Al Reba is driven by a passion for bold science and groundbreaking innovation that transforms lives. With more than 25 years at Bristol Myers Squibb (BMS), Al has dedicated his career to delivering hope and life-changing medicines to patients around the world.

In February 2025, Reba was appointed Senior Vice President of Cardiovascular & Immunology Commercialization. In this role, he oversees US commercial and global commercial strategy for key blockbuster products, including Eliquis, one of the world’s leading cardiovascular treatments that has benefited over fifty million patients, and Camzyos, a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy. He also spearheads the commercialization of milvexian, in collaboration with Johnson & Johnson, and leads the Immunology business unit, managing a portfolio that includes Orencia and Sotyktu.

Since joining BMS in 1999, Reba has taken on roles of increasing responsibility across diverse therapeutic areas, including cardiovascular, neuroscience, metabolics, and oncology. Highlights of his career include serving as the US launch lead for Eliquis (2008–2014), General Manager of BMS Canada (2017–2021), Senior Vice President of Worldwide Cardiovascular and Established Brands (2021–2023), and most recently, Senior Vice President of U.S. Cardiovascular and Established Brands (2023–2024). Prior to BMS, he worked with Andersen Consulting as an information technology and strategy consultant.

Reba earned his BS in Industrial Engineering and Operations Research from Cornell University. He holds an MBA from the University of Michigan Business School. He currently lives in Montgomery, NJ, with his wife, Judy, and their three children, Caitlyn, Ethan, and Jack.